Phosphodiesterase Isoform-specific Expression Induced by Traumatic Brain Injury

Overview

Journal J Neurochem

Specialties Chemistry
Neurology

Date 2012 Oct 13

PMID 23057870

Citations 20

Authors

Anthony A Oliva Jr

Yuan Kang

Concepcion Furones

Ofelia F Alonso

Olga Bruno

W Dalton Dietrich

Coleen M Atkins

Affiliations

Soon will be listed here.

Abstract

Traumatic brain injury (TBI) results in significant inflammation which contributes to the evolving pathology. Previously, we have demonstrated that cyclic AMP (cAMP), a molecule involved in inflammation, is down-regulated after TBI. To determine the mechanism by which cAMP is down-regulated after TBI, we determined whether TBI induces changes in phosphodiesterase (PDE) expression. Adult male Sprague Dawley rats received moderate parasagittal fluid-percussion brain injury (FPI) or sham injury, and the ipsilateral, parietal cortex was analyzed by western blotting. In the ipsilateral parietal cortex, expression of PDE1A, PDE4B2, and PDE4D2, significantly increased from 30 min to 24 h post-injury. PDE10A significantly increased at 6 and 24 h after TBI. Phosphorylation of PDE4A significantly increased from 6 h to 7 days post-injury. In contrast, PDE1B, PD4A5, and PDE4A8 significantly decreased after TBI. No changes were observed with PDE1C, PDE3A, PDE4B1/3, PDE4B4, PDE4D3, PDE4D4, PDE8A, or PDE8B. Co-localization studies showed that PDE1A, PDE4B2, and phospho-PDE4A were neuronally expressed, whereas PDE4D2 was expressed in neither neurons nor glia. These findings suggest that therapies to reduce inflammation after TBI could be facilitated with targeted therapies, in particular for PDE1A, PDE4B2, PDE4D2, or PDE10A.

Citing Articles

PDE4D: A Multipurpose Pharmacological Target.

Lusardi M, Rapetti F, Spallarossa A, Brullo C Int J Mol Sci. 2024; 25(15).

PMID: 39125619 PMC: 11311937. DOI: 10.3390/ijms25158052.

Therapeutic efficacy of rolipram delivered by PgP nanocarrier on secondary injury and motor function in a rat TBI model.

Macks C, Jeong D, Lee J Nanomedicine (Lond). 2022; 17(7):431-445.

PMID: 35184609 PMC: 8905552. DOI: 10.2217/nnm-2021-0271.

The Emerging Role of Phosphodiesterases in Movement Disorders.

Erro R, Mencacci N, Bhatia K Mov Disord. 2021; 36(10):2225-2243.

PMID: 34155691 PMC: 8596847. DOI: 10.1002/mds.28686.

Preclinical Western Blot in the Era of Digital Transformation and Reproducible Research, an Eastern Perspective.

Sargolzaei S, Kaushik A, Soltani S, Amini M, Khalghani M, Khoshavi N Interdiscip Sci. 2021; 13(3):490-499.

PMID: 34080131 DOI: 10.1007/s12539-021-00442-7.

Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Przybylowska M, Dzierzbicka K, Kowalski S, Chmielewska K, Inkielewicz-Stepniak I Curr Neuropharmacol. 2020; 19(8):1323-1344.

PMID: 33342413 PMC: 8719290. DOI: 10.2174/1570159X19666201218103434.

References

Oliva Jr A, Kang Y, Sanchez-Molano J, Furones C, Atkins C . STAT3 signaling after traumatic brain injury. J Neurochem. 2011; 120(5):710-20. DOI: 10.1111/j.1471-4159.2011.07610.x. View

Fatemi S, King D, Reutiman T, Folsom T, Laurence J, Lee S . PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res. 2008; 101(1-3):36-49. DOI: 10.1016/j.schres.2008.01.029. View

Mackenzie S, Baillie G, McPhee I, Mackenzie C, Seamons R, McSorley T . Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol. 2002; 136(3):421-33. PMC: 1573369. DOI: 10.1038/sj.bjp.0704743. View

Li Y, Cheng Y, Huang Y, Conti M, Wilson S, ODonnell J . Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci. 2011; 31(1):172-83. PMC: 3079568. DOI: 10.1523/JNEUROSCI.5236-10.2011. View

Atkins C, Kang Y, Furones C, Truettner J, Alonso O, Dietrich W . Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury. J Neurosci Res. 2012; 90(9):1861-71. PMC: 3418599. DOI: 10.1002/jnr.23069. View

Seeger T, Bartlett B, Coskran T, Culp J, James L, Krull D . Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003; 985(2):113-26. DOI: 10.1016/s0006-8993(03)02754-9. View

Tilley D, Maurice D . Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol. 2002; 62(3):497-506. DOI: 10.1124/mol.62.3.497. View

Block F, Schmidt W, Nolden-Koch M, Schwarz M . Rolipram reduces excitotoxic neuronal damage. Neuroreport. 2001; 12(7):1507-11. DOI: 10.1097/00001756-200105250-00041. View

Li L, Cheng Y, Lin H, Wang C, Xu J, Zhang H . Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. Metab Brain Dis. 2011; 26(1):37-47. DOI: 10.1007/s11011-011-9235-0. View

10.

Suda S, Nibuya M, Ishiguro T, Suda H . Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem. 1998; 71(4):1554-63. DOI: 10.1046/j.1471-4159.1998.71041554.x. View

11.

Sun D, Deshpande L, Sombati S, Baranova A, Wilson M, Hamm R . Traumatic brain injury causes a long-lasting calcium (Ca2+)-plateau of elevated intracellular Ca levels and altered Ca2+ homeostatic mechanisms in hippocampal neurons surviving brain injury. Eur J Neurosci. 2008; 27(7):1659-72. PMC: 2617755. DOI: 10.1111/j.1460-9568.2008.06156.x. View

12.

Temple M, Delahunty T, Hamm R, Phillips L, Lyeth B, Povlishock J . Subtle alterations in NMDA-stimulated cyclic GMP levels following lateral fluid percussion brain injury. J Neurotrauma. 2001; 18(1):47-55. DOI: 10.1089/089771501750055767. View

13.

Williams G, Morris M, Schache A, McCrory P . Incidence of gait abnormalities after traumatic brain injury. Arch Phys Med Rehabil. 2009; 90(4):587-93. DOI: 10.1016/j.apmr.2008.10.013. View

14.

Dietrich W, Chatzipanteli K, Vitarbo E, Wada K, Kinoshita K . The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. Acta Neurochir Suppl. 2004; 89:69-74. DOI: 10.1007/978-3-7091-0603-7_9. View

15.

Lakics V, Karran E, Boess F . Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010; 59(6):367-74. DOI: 10.1016/j.neuropharm.2010.05.004. View

16.

Manning C, Burman M, Christensen S, Cieslinski L, Essayan D, Grous M . Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999; 128(7):1393-8. PMC: 1571768. DOI: 10.1038/sj.bjp.0702911. View

17.

Ahmed T, Frey J . Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro. Brain Res. 2005; 1041(2):212-22. DOI: 10.1016/j.brainres.2005.02.023. View

18.

Morganti-Kossmann M, Satgunaseelan L, Bye N, Kossmann T . Modulation of immune response by head injury. Injury. 2007; 38(12):1392-400. DOI: 10.1016/j.injury.2007.10.005. View

19.

Verghese M, McConnell R, Strickland A, Gooding R, Stimpson S, Yarnall D . Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther. 1995; 272(3):1313-20. View

20.

DSa C, Tolbert L, Conti M, Duman R . Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem. 2002; 81(4):745-57. DOI: 10.1046/j.1471-4159.2002.00878.x. View